Enhabit (EHAB) Stock Forecast & Price Target

$7.44 -0.17 (-2.23%)

(As of 11/14/2024 ET)

Enhabit - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Reduce

Based on 7 Analyst Ratings

Sell
1

Hold
6

Buy
0

Based on 7 Wall Street analysts who have issued ratings for Enhabit in the last 12 months, the stock has a consensus rating of "Reduce." Out of the 7 analysts, 1 has given a sell rating, and 6 have given a hold rating for EHAB.

Consensus Price Target

$9.35
25.67% Upside

According to the 7 analysts' twelve-month price targets for Enhabit, the average price target is $9.35. The highest price target for EHAB is $12.00, while the lowest price target for EHAB is $8.00. The average price target represents a forecasted upside of 25.67% from the current price of $7.44.

Get the Latest News and Ratings for EHAB and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Enhabit and its competitors.

EHAB Analyst Ratings Over Time

Type	Current Forecast 11/15/23 to 11/14/24	1 Month Ago 10/16/23 to 10/15/24	3 Months Ago 8/17/23 to 8/16/24	1 Year Ago 11/15/22 to 11/15/23
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	0 Buy rating(s)	0 Buy rating(s)	0 Buy rating(s)	1 Buy rating(s)
Hold	6 Hold rating(s)	6 Hold rating(s)	6 Hold rating(s)	4 Hold rating(s)
Sell	1 Sell rating(s)	1 Sell rating(s)	1 Sell rating(s)	3 Sell rating(s)
Consensus Price Target	$9.35	$9.35	$9.35	$14.29
Forecasted Upside	25.67% Upside	30.77% Upside	11.84% Upside	46.07% Upside
Consensus Rating	Reduce	Reduce	Reduce	Reduce

The next assassination attempt won’t be on Trump (Ad)

President Trump is soon to be back in the White House. Unity has been restored to the U.S. But if you watched the President’s 25-minute victory speech, you probably noticed he spent nearly four minutes speaking about one very controversial person.

I share with you in this special investigative documentary.

EHAB Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

EHAB Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Enhabit Stock vs. The Competition

Type	Enhabit	Medical Companies	S&P 500
Consensus Rating Score	1.86	2.80	2.50
Consensus Rating	Reduce	Moderate Buy	Moderate Buy
Predicted Upside	25.67% Upside	26,227.51% Upside	8.88% Upside
News Sentiment Rating	Neutral News See Recent EHAB News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
6/27/2024	Bank of America 4 of 5 stars		Lower Target	Underperform ➝ Underperform	$9.00 ➝ $8.00	-1.84%
5/14/2024	Leerink Partnrs 5 of 5 stars	W. Mayo Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
5/14/2024	Leerink Partners 1 of 5 stars		Upgrade	Underperform ➝ Market Perform	$8.50	-1.62%
5/9/2024	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Buy ➝ Hold	$14.00 ➝ $8.75	-9.70%
3/7/2024	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Market Perform ➝ Market Perform
3/7/2024	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Sell ➝ Neutral	$9.50	+21.64%
12/12/2023	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Market Perform	$12.00	+11.63%
8/11/2023	Credit Suisse Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Neutral ➝ Neutral	$15.00 ➝ $12.00	+1.52%
6/20/2023	SVB Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Underperform	$10.00	-19.09%
5/12/2023	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target		$18.00 ➝ $15.00	+17.19%
3/16/2023	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Neutral	$15.00	+5.26%
2/15/2023	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target		$17.00 ➝ $18.00	+12.57%
12/13/2022	CJS Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Market Perform	$18.00	+26.14%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Friday at 12:00 AM ET.

EHAB Forecast - Frequently Asked Questions

: According to the research reports of 7 Wall Street equities research analysts, the average twelve-month stock price forecast for Enhabit is $9.35, with a high forecast of $12.00 and a low forecast of $8.00.
: 7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Enhabit in the last twelve months. There is currently 1 sell rating and 6 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "reduce" EHAB shares.
: According to analysts, Enhabit's stock has a predicted upside of 25.67% based on their 12-month stock forecasts.
: Analysts like Enhabit less than other "medical" companies. The consensus rating for Enhabit is Reduce while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how EHAB compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top Rated Stocks

More Ratings Tools

Musk Says ‘Dollar Will Be Worth Nothing…’ (Ad)

Cash In On the Pro-Crypto America 27 experts reveal their top picks for 2025

Click here to reserve your seat at the Crypto Community Summit.

This page (NYSE:EHAB) was last updated on 11/14/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Enhabit (EHAB) Stock Forecast & Price Target